CC
MNTA

Clearline Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Clearline Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-94,144
Closed -$1.14M – 81
2014
Q2 		$1.14M Hold
94,144
– – 0.18% 48
2014
Q1 		$1.1M Buy
+94,144
New +$1.59M 0.25% 50

Other funds holding MNTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Clearline Capital's MNTA Position: Q3 2014 in Review

Clearline Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2014, closing a stake of 94,144 shares — an estimated $1.14M sold.

Clearline Capital first reported a position in MNTA in Q1 2014 and held it in 2 quarters. The position peaked at $1.14M in Q2 2014. 143 funds tracked by Wall St. Rank hold MNTA as of Q3 2014.

  • Clearline Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Clearline Capital sold 94,144 Momenta Pharmaceuticals, Inc. shares in Q3 2014, an estimated $1.14M.
  • Clearline Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
  • Clearline Capital's Momenta Pharmaceuticals, Inc. position peaked at $1.14M in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2014.

Based on Clearline Capital's 13F filing for Q3 2014, filed 14 Nov 2014.